Laboratorios Richmond (Argentina) India's Panacea Biotec to produce 100 million Sputnik V doses annually: RDIF. Virchow Biotech (India) RDIF is expected to complete technology transfer in April-June, after which full-scale commercial production of Sputnik V will begin, said the Russian sovereign fund, which is the global commercialization partner for the vaccine.
“We are glad to sign a cooperation agreement with RDIF to produce Sputnik V vaccine. Virchow’s proven capabilities in large-scale drug substance manufacturing should help meet the global demand for this vaccine," Virchow Biotech managing director Tummuru Murali Krishna Reddy said. Virchow Biotech is the fourth Indian company to sign a production agreement with RDIF, the other three being Hetero Biopharma, Gland Pharma, and Stelis Biopharma. Gland Pharma (India) Gland Pharma has partnered with the Russian Direct Investment Fund (RDIF) to make up to 252 million doses of Sputnik V, the Covid-19 vaccine developed in Moscow that is currently awaiting emergency authorisation in India.
The agreement is expected to boost India’s capacity to manufacture this vaccine to around 350 million doses a year. Hyderabad-headquartered Gland Pharma, a subsidiary of China’s Fosun Pharma, is the third drug maker to collaborate with RDIF for the Russian vaccine after Dr Reddy’s Laboratories and Hetero Biopharma. As per the terms of the agreement, Gland Pharma will first be given the know-how to make Sputnik V at its manufacturing facilities. “After successful technology transfer, Gland Pharma will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions,” the company told stock exchanges on Tuesday.
Stelis Biopharma (Bangalore, India) Developers of Russia’s Sputnik V vaccine have entered into a partnership with Stelis Biopharma, an India-based drugmaker, to produce 200 million doses of the COVID-19 vaccine.
Stelis is now the latest addition to the global production network for Sputnik V. The Russian Direct Investment Fund (RDIF), the company responsible for marketing the Sputnik vaccine abroad, announced the partnership on Friday, making Stelis – the biopharmaceutical division of Strides, an Indian pharma company – the most recent in a series of manufacturers RDIF signed agreements with. “We are delighted to announce our agreement with Stelis Biopharma for a significant capacity of Sputnik V,” said Kirill Dmitriev, CEO of RDIF, in a press release. Duopharma Biotech Bhd (Kuala Lumpur, Malaysia) KUALA LUMPUR (Jan 26): Duopharma Biotech Bhd has signed a deal with the Malaysian government to supply 6.4 million doses of the Russian-developed "Sputnik V" Covid-19 vaccine.
In a filing today, the group confirmed that it will procure and supply to the Ministry of Health (MoH) the vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology. Duopharma said its subsidiary, Duopharma (M) Sdn Bhd (DMSB), has signed a term sheet agreement with MoH and the Russian Direct Investment Fund (RDIF) to secure the 6.4 million doses of Sputnik V. RDIF is the appointed marketing agent for Gamaleya for all international markets, with established partnerships in India, China, and South Korea to manufacture the vaccine. Biocad (Russia) ST.
PETERSBURG—In August, President Vladimir Putin heralded the approval of a Russian vaccine against Covid-19. Officials promised to produce millions of doses by year’s end. GL Rapha (South Korea) It has been agreed that The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and GL Rapha, one of the leading South Korean bio-tech companies (including the subsidiary Hankook Korus Pharm) will produce over 150 million doses per year of the world’s first registered vaccine against COVID-19.
The parties intend to commence production in December 2020 and a rollout of the Sputnik V vaccine in January 2021. RDIF and GL Rapha will supply over 150 million doses per year produced in South Korea for global distribution. Tibet Rhodiola Pharma (China) Binnopharm (Russia) Adienne Pharma & Biotech SA (Milan) Photographer: Carolina Cabral Fernandez/Bloomberg Russia is pushing ahead with plans to make its Covid-19 vaccine in Europe, securing a deal to produce the Sputnik V shot in Italy and discussing production in Germany and France.
Adienne Pharma & Biotech SA signed an agreement to manufacture the vaccine at its production site in the Milan region, Antonio Francesco Di Naro -- the founder and president of the Lugano, Switzerland-based company -- told Bloomberg in an interview. The deal with Russia’s sovereign wealth fund RDIF is the first European production deal for the vaccine.
While Russia was first to approve a shot for the general public and promoted it as a way to help end the pandemic globally, it has been slower than some rivals to scale up output. GL Rapha (South Korea) Uniao Química (Brazil) Hetero (India) Hyderabad-based Hetero will work with the Russian Direct Investment Fund (RDIF) to produce 100 million doses of Covid-19 vaccine Sputnik V per year for India.
The parties plan to start the production of Sputnik V in the beginning of 2021, a statement said. Earlier this week, RDIF Chief Executive Officer Kirill Dimitriev had announced the Russia sovereign wealth fund’s plan to supply 1 billion doses of Sputnik V across the globe in 2021. RDIF claimed more than 50 countries had requested for over 1.2 billion doses of Sputnik V vaccine. It has forged partnerships in India, China, Brazil, Korea, Hungary, and some other locations. Consortium of South Korean biomedical companies (South Korea) Feb. 25 (UPI) -- A consortium of South Korean biomedical companies is to manufacture Russia's Sputnik V vaccine.
Industry sources in Korea said the consortium that includes firms Binex, ISU Abxis, Boryung Biopharma, Chong Kun Dang Bio, Quratis, Humendix and Andong Animal Cell Validation Support Center are in negotiations with the Russian Direct Investment Fund over specific production quantities and prices, South Korean news service EDaily reported Thursday.
According to Hankook Korus Pharm, a member of the consortium, South Korean firms are planning to produce at least 500 million doses of the Russian vaccine. The Russian fund has said one dose of Sputnik V will sell for about $10. Karaganda pharmaceutical complex (Kazakhstan) Moscow, December 21, 2020 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announce the launch of production of Sputnik V, the world’s first registered vaccine against coronavirus, – in Kazakhstan.
A validation batch was produced today at the Karaganda pharmaceutical complex. The batch will be sent for verification to the developer of the vaccine – the Gamaleya National Center. The Karaganda pharmaceutical complex is an innovative biotechnology production facility with necessary equipment and qualified personnel, in compliance with international standards.
Thus the production of the vaccine was organized in an unprecedented short period of time. Generium and Belmedpreparaty (Belarus) Moscow, February 26, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Generium, a high-end Russian pharmaceutical company, and Belmedpreparaty, the leading pharmaceutical manufacturer in the Republic of Belarus, are preparing to begin production of the world’s first registered vaccine against coronavirus, Sputnik V. The first batch of the Gam-COVID-Vak (Sputnik V) vaccine developed by the Gamaleya National Center has been produced for validation at Belmedpreparaty production facilities, utilizing technology transferred by the Russian company Generium. Upon obtaining the results of the stability study for the first batch of Sputnik V, preparations will begin for mass production.
RDIF and its partners are also working on testing the full-cycle technology used for Sputnik V production at facilities in the Republic of Belarus. Belarus became the second country in the world after Russia to officially register Sputnik V. For additional information contact: